Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAT-179
- Development stage
- Preclinical
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAT-179 is an allogeneic natural killer (NK) cell therapy product engineered to express a chimeric antigen receptor (CAR) targeting HER2, as well as interleukin-15 (IL-15) and transforming growth factor beta (TGFβ). This design aims to enhance NK cell persistence, proliferation, and anti-tumor activity while overcoming immunosuppressive signals in the tumor microenvironment. The primary indication under investigation for CAT-179 is renal cell carcinoma. As of the latest available information, development is at the preclinical stage[2].
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)IL15 (Interleukin 15)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on CAT-179.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAT-179.